Literature DB >> 1914340

Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

M J Eadie1.   

Abstract

All of the commonly used anticonvulsants drugs, except possibly primidone, are cleared from the human body mainly by metabolism. The metabolites of phenytoin, phenobarbital and ethosuximide have so far not been shown to possess significant pharmacological activity. However, carbamazepine-10,11-epoxide, derived from carbamazepine, has anticonvulsant activity comparable with that of its progenitor, while oxcarbazepine, a new anticonvulsant congener of carbamazepine, is essentially a prodrug for its 10-hydroxy derivative. Valproic acid forms numerous metabolites through a variety of pathways; 2-en valproic acid, a beta-oxidation derivative, probably contributes to its anticonvulsant action, though the extent of the contribution is uncertain. Another metabolite, 4-en-valproic acid, has been considered a possible hepatotoxin and teratogen. N-Methyl-phenobarbital and primidone, though both anticonvulsants in their own right, are metabolised to phenobarbital, which probably mediates much of their antiseizure effect. Primidone also yields the weaker anticonvulsant phenylethylmalonamide. The various benzodiazepine anticonvulsants form numerous metabolites, some of which possess both antiseizure and other forms of pharmacological activity. As yet, there is little understanding of how best to interpret simultaneous plasma concentration measurements of anticonvulsant drug and its active metabolite (or metabolites) in the clinical situation, and the possible roles of anticonvulsant metabolites in the idiosyncratic toxicity of these drugs remain largely unexplored.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914340     DOI: 10.2165/00003088-199121010-00003

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  74 in total

1.  The metabolic conversion of 5, 5-diphenyl hydantoin to 5-(p-hydroxyphenyl)-5-phenyl hydantoin.

Authors:  T C BUTLER
Journal:  J Pharmacol Exp Ther       Date:  1957-01       Impact factor: 4.030

2.  Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.

Authors:  H Nau
Journal:  Teratology       Date:  1986-02

3.  Titration of central-nervous-system depression.

Authors:  G CHEN; R PORTMAN
Journal:  AMA Arch Neurol Psychiatry       Date:  1952-10

4.  First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.

Authors:  R G Dickinson; W D Hooper; P R Dunstan; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Pharmacokinetics of drugs used for petit mal 'absence' epilepsy.

Authors:  M J Eadie; J H Tyrer; G A Smith; L McKauge
Journal:  Clin Exp Neurol       Date:  1977

6.  Aspects of the metabolism of valproic acid.

Authors:  G R Granneman; S I Wang; J M Machinist; J W Kesterson
Journal:  Xenobiotica       Date:  1984-05       Impact factor: 1.908

7.  Disposition of mephenytoin and its metabolite, nirvanol, in epileptic patients.

Authors:  W H Theodore; M E Newmark; B T Desai; H J Kupferberg; J K Penry; R J Porter; W D Yonekawa
Journal:  Neurology       Date:  1984-08       Impact factor: 9.910

8.  Fatal liver failure in 16 children with valproate therapy.

Authors:  D Scheffner; S König; I Rauterberg-Ruland; W Kochen; W J Hofmann; S Unkelbach
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

9.  Phenylethylmalonamide (PEMA). An important metabolite of primidone.

Authors:  I P Baumel; B B Gallagher; R H Mattson
Journal:  Arch Neurol       Date:  1972-07

10.  Plasma levels of sodium valproate in childhood epilepsy.

Authors:  J K McQueen; D H Blackwood; R A Minns; J K Brown
Journal:  Scott Med J       Date:  1982-10       Impact factor: 0.729

View more
  5 in total

1.  In vivo binding characteristics of carbamazepine and carbamazepine-10,11-epoxide to serum proteins in paediatric patients with epilepsy.

Authors:  Y Kodama; K Tsutsumi; M Kuranari; H Kodama; I Fujii; M Takeyama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

2.  Increased sensitivity to the anticonvulsant effect of valproate in aging BN/BiRij rats.

Authors:  A M Stijnen; S Hovinga; M W Langemeijer; A Hoogerkamp; C F van Bezooijen; M Danhof
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

3.  The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.

Authors:  Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

4.  Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations.

Authors:  Akira Fujii; Norio Yasui-Furukori; Taku Nakagami; Takenori Niioka; Manabu Saito; Yasushi Sato; Sunao Kaneko
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

5.  Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells.

Authors:  Yuki Kondo; Takahiro Iwao; Sachimi Yoshihashi; Kayo Mimori; Ruri Ogihara; Kiyoshi Nagata; Kouichi Kurose; Masayoshi Saito; Takuro Niwa; Takayoshi Suzuki; Naoki Miyata; Shigeru Ohmori; Katsunori Nakamura; Tamihide Matsunaga
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.